On Tuesday, October 15th, at 11:15, Chordate's CEO Anders Weilandt will participate at the investor event Aktieportföljen. He will present the latest developments in the company, such as the first migraine order from Saudi Arabia, the breakthrough in Switzerland and the progress on the other focus markets, the new patent in the US, as well as the next step of the exit-strategy.
"It is important for us to get out and meet both existing and potential new shareholders. We want to seize every opportunity to inform the market, and Aktieportföljen gathers a large investor community," says Anders Weilandt, Chordate CEO.
Aktieportföljen runs an investor network on Facebook in Sweden and Denmark with a total of 150,000 members.
Aktieportföljen Live can be streamed on Direkt Studios Youtube channel, and viewed on-demand in the Aktieportföljen Facebook group.
For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.
N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.